Categories

Viral shedding

Oncolytic viruses, which include both naturally occurring wild-type viruses/attenuated viruses and genetically modified viruses, have recently been developed for use in innovative cancer therapies. Genetically modified oncolytic viruses possess the unique ability to replicate conditionally as a unique gene therapy product. Since oncolytic viruses exhibit prolonged persistence in patients, viral shedding and transmission to third parties should be major concerns for clinical trials along with the clinical safety and efficacy.

Shedding is linked to biodistribution studies but unlike biodistribution, which describes how a product is spread within the animal model’s or patient’s body from the site of administration, shedding describes how it is excreted or released from the body.

In Generi Biotech, we have vast experience with qPCR testing in different matrices, most commonly in:

  • excreta (feces)
  • secreta (urine, saliva, nasopharyngeal fluids etc.)
  • skin-related tissue biopsies (pustules, sores, wounds)
Useful links
Recommended products
gb OneStep RT-qPCR Kit

gb OneStep RT-qPCR Kit gb OneStep RT-qPCR Kit

gb OneStep RT-qPCR Kit falls into a group of TaqMan Real-Time PCR Master Mixes. It provides cDNA synthesis in one-step. The product is intended for reverse transcription (RT) and real-time PCR (qPCR) performed in one step (in one reaction), i.e. onestep RT-qPCR. No additional instrumentation is required.

More
Recommended articles